Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Clin Infect Dis ; 50(11): e63-8, 2010 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-20420515

RESUMO

We describe 3 cases of daptomycin-induced pulmonary toxic effects that are consistent with drug-induced acute eosinophilic pneumonia. Patients presented similarly with dyspnea, cough, hypoxia, and diffuse ground-glass opacities at chest computed tomography. Clinical suspicion for this adverse drug event and cessation of daptomycin until definitive diagnosis can be made is crucial.


Assuntos
Antibacterianos/efeitos adversos , Daptomicina/efeitos adversos , Eosinofilia Pulmonar/induzido quimicamente , Eosinofilia Pulmonar/diagnóstico , Idoso de 80 Anos ou mais , Humanos , Masculino , Pessoa de Meia-Idade , Eosinofilia Pulmonar/patologia , Radiografia Torácica , Tomografia
2.
Crit Care ; 12(5): 233, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18983709

RESUMO

Antipseudomonal carbapenems have played a useful role in our antimicrobial armamentarium for 20 years. However, a review of their use during that period creates concern that their clinical effectiveness is critically dependent on attainment of an appropriate dosing range. Unfortunately, adequate carbapenem dosing is missed for many reasons, including benefit/risk misconceptions, a narrow therapeutic window for imipenem and meropenem (due to an increased rate of seizures at higher doses), increasingly resistant pathogens requiring higher doses than are typically given, and cost containment issues that may limit their use. To improve the use of carbapenems, several initiatives should be considered: increase awareness about appropriate treatment with carbapenems across hospital departments; determine optimal dosing regimens for settings where multidrug resistant organisms are more likely encountered; use of, or combination with, an alternative antimicrobial agent having more favorable pharmacokinetic, pharmacodynamic, or adverse event profile; and administer a newer carbapenem with lower propensity for resistance development (for example, reduced expression of efflux pumps or greater stability against carbapenemases).


Assuntos
Antibacterianos/efeitos adversos , Antibacterianos/uso terapêutico , Carbapenêmicos/efeitos adversos , Carbapenêmicos/uso terapêutico , Infecções por Pseudomonas/tratamento farmacológico , Infecções por Pseudomonas/economia , Pseudomonas aeruginosa , Animais , Antibacterianos/economia , Antibacterianos/farmacologia , Carbapenêmicos/economia , Carbapenêmicos/farmacologia , Ensaios Clínicos como Assunto/efeitos adversos , Ensaios Clínicos como Assunto/economia , Humanos , Pseudomonas aeruginosa/efeitos dos fármacos
3.
Crit Care ; 12 Suppl 4: S4, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18495061

RESUMO

Resistance rates are increasing among several problematic Gram-negative pathogens that are often responsible for serious nosocomial infections, including Acinetobacter spp., Pseudomonas aeruginosa, and (because of their production of extended-spectrum beta-lactamase) Enterobacteriaceae. The presence of multiresistant strains of these organisms has been associated with prolonged hospital stays, higher health care costs, and increased mortality, particularly when initial antibiotic therapy does not provide coverage of the causative pathogen. Conversely, with high rates of appropriate initial antibiotic therapy, infections caused by multiresistant Gram-negative pathogens do not negatively influence patient outcomes or costs. Taken together, these observations underscore the importance of a 'hit hard and hit fast' approach to treating serious nosocomial infections, particularly when it is suspected that multiresistant pathogens are responsible. They also point to the need for a multidisciplinary effort to combat resistance, which should include improved antimicrobial stewardship, increased resources for infection control, and development of new antimicrobial agents with activity against multiresistant Gram-negative pathogens.


Assuntos
Antibacterianos/uso terapêutico , Infecções por Bactérias Gram-Negativas/tratamento farmacológico , Antibacterianos/economia , Infecção Hospitalar/tratamento farmacológico , Infecção Hospitalar/economia , Farmacorresistência Bacteriana , Resistência a Múltiplos Medicamentos , Bactérias Gram-Negativas/efeitos dos fármacos , Infecções por Bactérias Gram-Negativas/economia , Humanos , Testes de Sensibilidade Microbiana , Fatores de Risco
5.
Am J Med ; 118 Suppl 7A: 1S-6S, 2005 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15993671

RESUMO

In response to the overuse and misuse of antibiotics, leading to increasing bacterial resistance and decreasing development of new antibiotics, the Council for Appropriate and Rational Antibiotic Therapy (CARAT) has developed criteria to guide appropriate and accurate antibiotic selection. The criteria, which are aimed at optimizing antibiotic therapy, include evidence-based results, therapeutic benefits, safety, optimal drug for the optimal duration, and cost-effectiveness.


Assuntos
Antibacterianos/administração & dosagem , Infecções Bacterianas/tratamento farmacológico , Uso de Medicamentos/normas , Antibacterianos/economia , Antibacterianos/farmacocinética , Análise Custo-Benefício , Humanos , Seleção de Pacientes
6.
J Fam Pract ; Suppl: S15-7, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15938990

RESUMO

Identification of risk factors present in the medical history should alert physicians to patients at potentially high risk for drug-induced QT interval prolongation. Careful patient monitoring and treatment adjustment will aid physicians in avoiding the complications of QT interval prolongation.


Assuntos
Síndrome do QT Longo/prevenção & controle , Antiarrítmicos/efeitos adversos , Eletrocardiografia , Feminino , Humanos , Síndrome do QT Longo/induzido quimicamente , Síndrome do QT Longo/diagnóstico , Masculino , Anamnese , Medição de Risco/métodos , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa